Microcytosis in Erythropoietic Protoporphyria
- PMID: 35309058
- PMCID: PMC8928159
- DOI: 10.3389/fphys.2022.841050
Microcytosis in Erythropoietic Protoporphyria
Abstract
Partial deficiency of the last enzyme of the heme biosynthetic pathway, namely, ferrochelatase (FECH), is responsible for erythropoietic protoporphyria (EPP) in humans. This disorder is characterized by painful skin photosensitivity, due to excessive protoporphyrin IX (PPIX) production in erythrocytes. Although several papers report the presence of iron deficiency anemia in about 50% of EPP patients, there is still no a conclusive explanation of the why this occurs. In the present work, we explored hematological indices and iron status in 20 unrelated Italian EPP patients in order to propose a new hypothesis. Our data show that microcytosis is present in EPP patients also in the absence of anemia and iron deficiency with a link between PPIX accumulation and reduced MCV, probably indicating an indirect condition of heme deficiency. Patients studied had a downward shift of iron parameters due to increased hepcidin concentrations only in a state of repleted iron stores. Interestingly, hemoglobin synthesis was not limited by iron supply except in cases with further iron loss, in which concomitantly increased soluble transferrin (Tf) receptor (sTfR) levels were detected. The mechanisms involved in the iron uptake downregulation in EPP remain unclear, and the role of PPIX accumulation in microcytosis.
Keywords: PPIX accumulation; anemia; erythropoietic protoporphyria; hepcidin; iron and heme deficiency; microcytosis.
Copyright © 2022 Graziadei, Duca, Granata, De Luca, De Giovanni, Brancaleoni, Nava and Di Pierro.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



References
-
- Balwani M., Naik H., Anderson K. E., Bissell D. M., Bloomer J., Bonkovsky H. L., et al. . (2017). Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA Dermatol. 153, 789–796. doi: 10.1001/jamadermatol.2017.1557, PMID: - DOI - PMC - PubMed
-
- Barman-Aksozen J., Beguin C., Dogar A. M., Schneider-Yin X., Minder E. I. (2013). Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF65. Blood Cells Mol. Dis. 51, 151–161. doi: 10.1016/j.bcmd.2013.05.008, PMID: - DOI - PubMed
-
- Barman-Aksoezen J., Girelli D., Aurizi C., Schneider-Yin X., Campostrini N., Barbieri L., et al. . (2017). Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. J. Inherit. Metab. Dis. 40, 433–441. doi: 10.1007/s10545-017-0017-7, PMID: - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous